A question worth carrying
Keep the paper with the finding
Here are the sources behind the pages, with a few words about what each one can tell us.
What was studied?
The GHRH family in health and disease
Granata and colleagues · Nature Reviews Endocrinology · 2025
Explains growth hormone-releasing hormone (GHRH) and its shared receptor, a receiving point on a cell. Sharing a receptor does not mean sharing benefits.
Putting a name to an unknown preparation
Drug Testing and Analysis · Henninge et al. (2010)
Identified CJC-1295 in one unknown pharmaceutical preparation. That result does not show treatment benefit or how often other products are mislabeled.
FDA’s review of the CJC-1295 forms
FDA · Pharmacy Compounding Advisory Committee materials · December 2024
Examines two different active ingredients, with and without DAC, across five chemical forms. DAC helps the peptide last longer. The two active ingredients cannot be swapped; salt forms also matter.
A name connects the right paper
These documents sort out names. They cannot verify the contents of a product you encounter elsewhere.
Who took part, and what changed?
Growth measured in children with a deficiency
Thorner and colleagues · Journal of Clinical Endocrinology and Metabolism · 1996
Children before puberty with growth hormone deficiency grew faster during the first year. Treatment was known, with no comparison group. Final adult height was not established.
Sermorelin’s pediatric and diagnostic record
Prakash and Goa · BioDrugs · 1999
Covers sermorelin’s former test and childhood treatment uses, plus older side-effect findings. Those findings cannot supply current adult risk rates.
Hormone changes over two weeks in older men
Corpas and colleagues · Journal of Clinical Endocrinology and Metabolism · 1992
A small, two-week study in healthy older men found hormone changes. Lasting improvements in sleep, strength or energy were not established.
Tesamorelin and deep abdominal fat in adults with HIV
New England Journal of Medicine · Falutz et al. (2007)
Tesamorelin reduced deep abdominal fat compared with placebo, a dummy treatment, in adults with HIV and excess belly fat. This was not a general weight-loss trial.
The longer CJC-1295 signal in healthy adults
Teichman and colleagues · Journal of Clinical Endocrinology and Metabolism · 2006
Found a lasting hormone response in healthy adults. FDA says the work appears to have used DAC, without specifying the salt. Sleep, muscle and aging benefits were not established.
Different results need different words
These measurements answer different questions. The papers do not form a head-to-head comparison or supply a personal treatment plan.
What do the official documents say?
The EGRIFTA WR prescribing information
Tesamorelin product labeling · DailyMed
Gives this tesamorelin product’s approved use, warnings and follow-up instructions. Records fat returning after a switch to placebo. Its instructions belong to this medicine.
The withdrawn nominations and the remaining safety concerns
FDA · page content current as of April 22, 2026
Lists CJC-1295 as nominated but withdrawn, with safety concerns attached. Withdrawal gives no compounding permission. The page date is not an individual withdrawal date.
What compounding does and does not mean
FDA · Compounding questions and answers
Compounded medicines are not FDA-approved. FDA does not check their safety, effectiveness or quality before marketing. Having a prescription does not change that.
The finding about the former sermorelin products
FDA · Federal Register · 2013
FDA found the former sermorelin products were not withdrawn for safety or effectiveness reasons. This does not approve a compounded product or establish adult wellness benefits.
Keep each decision in its place
A product label applies to its medicine. The historical finding concerns the former sermorelin products. Today’s compounded medicines are not FDA-approved.